A cost comparison of oral tegafur plus uracil/folinic acid and parenteral fluorouracil for colorectal cancer in Canada.
D000284:Administration, Oral; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use; D002170:Canada; D017326:Clinical Trials, Phase III as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000191:economics* / Q000473:pathology; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use; D017048:Health Care Costs; D006801:Humans; D007263:Infusions, Parenteral; D002955:Leucovorin / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D005641:Tegafur / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use; D014498:Uracil / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use
D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; D005641:Tegafur; D014498:Uracil; D002955:Leucovorin; D005472:Fluorouracil